

Chapter 9

Revolutionizing Drug Development: Navigating the Convergence of Artificial Intelligence and Pharmaceutical Innovation

K. S. Giriprasath

PSG Institute of Technology and Applied Research, Coimbatore, India

P. Pandiyarajan

Hindusthan Institute of Technology, Coimbatore, India

C. Santhosh

PSG Institute of Technology and Applied Research, Coimbatore, India

K. Aneesh

Rathinam College of Arts and Science, India

R. Vasanth

 <https://orcid.org/0000-0002-0295-8015>

Department of Computing Technologies, School of Computing, College of Engineering and Technology, SRM Institute of Science and Technology, Chengalpattu, India

ABSTRACT

A disruptive age has begun with the convergence of drug development with artificial intelligence (AI), which has profoundly changed the field's traditional boundaries and potential. This chapter explores the numerous uses of artificial intelligence in the complex network of drug development. Through a thorough examination of the complex interactions between artificial intelligence (AI) and the intricacies of the

DOI: 10.4018/979-8-3693-5468-1.ch009

Revolutionizing Drug Development

drug development process, this chapter provides a sophisticated understanding of the difficulties encountered and the new opportunities that have arisen from this mutually beneficial partnership. This chapter provides a thorough description of the opportunities and challenges that are always changing within this quickly developing industry, acting as a compass for navigating the challenges associated in exploiting AI's potential in the field of drug discovery. By setting the foundation for ground-breaking findings, this chapter significantly advances our understanding and the growing integration of AI in the field of drug development.

I. INTRODUCTION

A. Disruption in Drug Development With the Convergence of Artificial Intelligence (AI)

Artificial Intelligence (AI) is bringing about a revolution in the drug research industry, bringing with it previously unheard-of efficiencies and creative discoveries. The combination of artificial intelligence with medication development has created a disruptive force that is speeding up the pace of discovery and commercialization and altering established paradigms. Almost every stage is being revolutionized by AI. AI is accelerating discovery, increasing efficiency, and ushering in a new era of precision medicine. It can be used to mine enormous databases to forecast interesting drug targets and customize treatment plans, or it can be used to streamline clinical trials by discovering perfect volunteers and optimizing dosing regimens. AI's capacity to forecast demand, maximize output, and guarantee quality control even extends to the pharmaceutical manufacturing and supply chains, ultimately resulting in quicker research and greater accessibility to life-saving therapies.

In the past, developing new drugs has required a lot of time and resources, and the success rates are frequently lower than anticipated. By providing innovative answers to enduring problems, the incorporation of AI technologies is transforming this story. Researchers can now evaluate large datasets with previously unheard-of speed and precision thanks to machine learning algorithms, deep learning models, and other AI-driven techniques. Potential therapeutic targets, biomarkers, and drug candidates can now be identified with previously unachievable insight thanks to this data-centric approach.

AI's capacity to interpret intricate biological correlations and patterns in massive datasets is one of its main advantages in the drug development process (Vora et al., 2023). It also makes it easier to identify possible side effects, patient response to treatment, and subtle markers of disease progression. At every stage of drug